Arsène Mekinian, Lucie Biard, Dagna Lorenzo, Pavel I Novikov, Carlo Salvarani, Olivier Espitia, Savino Sciascia, Martin Michaud, Marc Lambert, José Hernández-Rodríguez, Nicolas Schleinitz, Abid Awisat, Xavier Puechal, Achille Aouba, Helene Munoz Pons, Ilya Smitienko, Jean Baptiste Gaultier, Le Mouel Edwige, Ygal Benhamou, Antoinette Perlat, Patrick Jego, Tiphaine Goulenok, Karim Sacre, Bertrand Lioger, Nolan Hassold, Jonathan Broner, Virginie Dufrost, Thomas Sené, Julie Seguier, Francois Maurier, Sabine Berthier, Alexandre Belot, Faten Frikha, Guillaume Denis, Alexandra Audemard-Verger, Isabelle Koné-Paut, Sebastien Humbert, Pascal Woaye-Hune, Alessandro Tomelleri, Elena Marina Baldissera, Masataka Kuwana, Alberto Logullo, Vahan Mukuchyan, Azeddine Dellal, Francis Gaches, Pierre Zeminsky, Elena Galli, Moya Alvarado, Luigi Boiardi, Muratore Francesco, Mathieu Vautier, Campochiaro Corrado, Sergey Moiseev, Matheus Vieira, Patrice Cacoub, Olivier Fain, David Saadoun
OBJECTIVES: In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients. METHODS: We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019. RESULTS: A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study...
June 2023: RMD Open